The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
What are the unique challenges to CMV prophylaxis in patients with acute or chronic GvHD?
Featured:
Delaney WolfeDuring the 2021 ASCO Annual Meeting, the GvHD Hub spoke with Delaney Wolfe, The Ohio State University, Columbus, US. We asked, What are the unique challenges to cytomegalovirus (CMV) prophylaxis in patients with acute or chronic GvHD?
What are the unique challenges to CMV prophylaxis in patients with acute or chronic GvHD?
Wolfe evaluates the use of letermovir for CMV prophylaxis. This includes the need for long-term data that observes treatment past day 100 post-allo-HCT, the challenges for CMV monitoring in patients who progress to chronic GvHD, and whether the benefits of letermovir outweigh its costs.